Cytovia Therapeutics
Boris Reznik is the Chairman of Venvalo Group. During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed high growth, profitable enterprises and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in multiple technology-based companies and has participated in many public and private fundings and mergers and acquisitions of technology-based companies.
This person is not in the org chart
This person is not in any offices
Cytovia Therapeutics
2 followers
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.